Martha Demski - Equillium Independent Director
| EQ Stock | USD 1.79 0.06 3.24% |
Director
Ms. Martha J. Demski is Independent Director of the company since September 2018. From August 2011 to May 2017, Ms. Demski served as Senior Vice President and Chief Financial Officer of Ajinomoto Althea, Inc., a privatelyheld fullyintegrated contract development and manufacturing organization. From July 2008 to December 2010, Ms. Demski served as the Interim Chief Operating Officer and Chief Financial Officer of the Sidney Kimmel Cancer Center, a nonprofit corporation that was engaged in biomedical research prior to voluntarily filing for Chapter 11 bankruptcy in 2009. Previously, Ms. Demski served as Vice President and Chief Financial Officer of Vical Incorporated, a publiclyheld biopharmaceutical company, from December 1988 to June 2004. Ms. Demski currently serves as the chair of the board of directors of Chimerix, Inc., a publiclyheld biopharmaceutical company, and on the board of directors, as the chair of the audit committee and as a member of the compensation and finance committees, of Adamas Pharmaceuticals, Inc., a publiclyheld biotechnology company. Prior to 2018, Ms. Demski was a member of the board of directors, chair of the audit committee and member of the compensation committee, nominating and governance committee, and operating committee of Neothetics, Inc., a publiclyheld biotechnology company. Ms. Demski is a National Association of Corporationrationrate Directors Board Governance Fellow. In 2017, she received the Director of the Year in Corporationrationrate Governance award by the Corporationrationrate Directors Forum. Additionally, Ms. Demski has over 13 years of banking experience with Bank of America and U.S. Trust since 2018.
| Age | 65 |
| Tenure | 6 years |
| Professional Marks | MBA |
| Address | 2223 Avenida De La Playa, La Jolla, CA, United States, 92037 |
| Phone | 858 240 1200 |
| Web | https://www.equilliumbio.com |
Equillium Management Efficiency
The company has Return on Asset (ROA) of (0.1408) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1408. This is way below average. Likewise, it shows a return on total equity (ROE) of (0.4892) %, which implies that it produced no returns to current stockholders. Equillium's management efficiency ratios could be used to measure how well Equillium manages its routine affairs as well as how well it operates its assets and liabilities. As of 04/19/2024, Return On Tangible Assets is likely to drop to -0.28. In addition to that, Return On Capital Employed is likely to drop to -0.66. At this time, Equillium's Total Current Liabilities is relatively stable compared to the past year. As of 04/19/2024, Liabilities And Stockholders Equity is likely to grow to about 67.5 M, while Non Current Liabilities Total is likely to drop slightly above 364.8 K.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Lewis Hay | AN2 Therapeutics | 60 | |
| Srinivas Akkaraju | aTyr Pharma | 47 | |
| Elizabeth Tallett | AN2 Therapeutics | 67 | |
| Guillermo Gabella | Bolt Biotherapeutics | N/A | |
| William Ryan | AN2 Therapeutics | 71 | |
| Ali Satvat | Coherus BioSciences | 40 | |
| JeanFrancois Formela | Spero Therapeutics | 60 | |
| Barry Simon | Cue Biopharma | 53 | |
| David Southwell | Spero Therapeutics | 56 | |
| Frank Morich | Cue Biopharma | 63 | |
| Jran Zhang | Bolt Biotherapeutics | 49 | |
| Vikas Goyal | Spero Therapeutics | 37 | |
| Anibal Bernardo | Bolt Biotherapeutics | N/A | |
| Cynthia Smith | Spero Therapeutics | 49 | |
| Christos Richards | Coherus BioSciences | 59 | |
| Timothy Coughlin | aTyr Pharma | 51 | |
| Amir Nashat | aTyr Pharma | 44 | |
| James Blair | aTyr Pharma | 78 | |
| Antonio Neri | AN2 Therapeutics | 49 | |
| Will Feest | AN2 Therapeutics | N/A | |
| Paul Schimmel | aTyr Pharma | 77 | |
Management Performance
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 |
Equillium Leadership Team
Elected by the shareholders, the Equillium's board of directors comprises two types of representatives: Equillium inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Equillium. The board's role is to monitor Equillium's management team and ensure that shareholders' interests are well served. Equillium's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Equillium's outside directors are responsible for providing unbiased perspectives on the board's policies.
| John Fisher, Independent Director | ||
| Jason Keyes, Chief Officer | ||
| Penny Tom, Principal Officer | ||
| Anthony Tjan, Independent Director | ||
| Daniel Bradbury, Chairman of the Board, CEO | ||
| Joel Rothman, Chief Officer | ||
| Krishna Polu, Chief Medical Officer | ||
| Marc Lavine, Independent Director | ||
| Charles McDermott, Independent Director | ||
| Bruce Steel, President Chief Business Officer and Director | ||
| PMP MBA, Senior COO | ||
| Matthew Ritter, Senior Development | ||
| Maple MD, Chief Officer | ||
| Krishna MD, Consultant | ||
| Geoffrey Rotstein, President CEO, Director | ||
| Bruce CFA, President, CoFounder | ||
| Bala Manian, Independent Director | ||
| Michael Moore, Vice Communications | ||
| Dilshan Kathriarachchi, CTO | ||
| Stephen Connelly, Chief Scientific Officer, Director | ||
| Peter Kanniah, CFO, Secretary | ||
| Martha Demski, Independent Director | ||
| Mark Pruzanski, Independent Director | ||
| Vernon Lobo, Independent Chairman of the Board |
Equillium Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Equillium a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.49 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0.37) % | ||||
| Operating Margin | (0.35) % | ||||
| Current Valuation | 20.95 M | ||||
| Shares Outstanding | 35.25 M | ||||
| Shares Owned By Insiders | 36.42 % | ||||
| Shares Owned By Institutions | 21.76 % | ||||
| Number Of Shares Shorted | 394.47 K | ||||
| Price To Earning | (6.70) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Equillium in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Equillium's short interest history, or implied volatility extrapolated from Equillium options trading.
Pair Trading with Equillium
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Equillium position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Equillium will appreciate offsetting losses from the drop in the long position's value.Moving together with Equillium Stock
| 0.67 | EOLS | Evolus Inc Financial Report 14th of May 2024 | PairCorr |
Moving against Equillium Stock
| 0.54 | LPTX | Leap Therapeutics Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Equillium could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Equillium when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Equillium - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Equillium to buy it.
The correlation of Equillium is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Equillium moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Equillium moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Equillium can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Equillium. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Equillium Stock, please use our How to Invest in Equillium guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Equillium Stock analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Equillium's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Equillium. If investors know Equillium will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Equillium listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.38) | Revenue Per Share 1.039 | Quarterly Revenue Growth (0.42) | Return On Assets (0.14) | Return On Equity (0.49) |
The market value of Equillium is measured differently than its book value, which is the value of Equillium that is recorded on the company's balance sheet. Investors also form their own opinion of Equillium's value that differs from its market value or its book value, called intrinsic value, which is Equillium's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Equillium's market value can be influenced by many factors that don't directly affect Equillium's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Equillium's value and its price as these two are different measures arrived at by different means. Investors typically determine if Equillium is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Equillium's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.